CHILDREN’S HEALTH DEFENSE DEMANDS FDA WITHDRAW ITS APPROVAL OF REMDESIVIR FOR INFANTS AND CHILDREN, CITING 72% ADVERSE EVENTS RATE
Drug is highly toxic to adults; COVID poses virtually zero threat to this age group and unfinished drug trial reflects poor efficacy and safety evidence By Children’s Health Defense Article Source The U.S. Food and Drug...
Read More